TITLE:
Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia

CONDITION:
Schizophrenia

INTERVENTION:
Quetiapine Fumarate

SUMMARY:

      The purpose of this study is to demonstrate superior efficacy of sustained release
      quetiapine compared to placebo in patients with schizophrenia after receiving treatment for
      up to 6 weeks.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        Inclusion Criteria:

          -  Patient is able to provide written informed consent before beginning any study
             related procedures

          -  Patient has a documented clinical diagnosis of schizophrenia

          -  Patient is able to understand and comply with the requirements of the study, as
             judged by a study investigator

        Exclusion Criteria:

          -  Patients with a history of non-compliance as judged by the study investigator

          -  Patients with a known lack of response to previous treatment with quetiapine

          -  Patients who have participated in another drug study within 4 weeks prior to
             enrollment into this study

          -  Patients who have previously participated in this study or study D1444C00132
      
